Full Press Release Details
to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and
Host Conference Call on November 13, 2023
Israel, and Hoboken, NJ, November 8, 2023 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company
with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today
announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open
of the U.S. financial markets on Monday, November 13, 2023.
management will host an investment community conference call on Monday, November 13, at 8:30am Eastern Time to discuss these results
and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from
within the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference ID 13741701. The call will also be webcast
live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1637192&tp_key=fd85a910fe.
call will also be archived for 90 days on the Company's website at www.kamada.com.
Ltd. (the "Company") is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated
for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives.
The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company's
strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development
expertise in the plasma-derived and biopharmaceutical fields. The Company's commercial products portfolio includes six FDA approved
plasma-derived biopharmaceutical products: CYTOGAM , KEDRAB , WINRHO SDF , VARIZIG , HEPAGAM B and GLASSIA ,
as well as KAMRAB , KAMRHO (D) and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial
products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S.,
Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, Middle East, and Asia. The
Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products
that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution
portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched
in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in
the collection of hyper-immune plasma used in the manufacture of KAMRHO (D). In addition to the Company's commercial operation,
it invests in research and development of new product candidates. The Company's leading investigational product is an inhaled AAT
for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind,
placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company's
lead shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.